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Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK 
Helena M Earl, Louise Hiller, Janet Dunn, Iain Macpherson, Daniel Rea, Luke Hughes-Davies, Karen 
McAdam, Peter Hall, Janine Mansi, Duncan Wheatley, Jean Abraham, Carlos Caldas, Sophie Gasson, 
Liz O'Riordan, Maggie Wilcox, David Miles, David Cameron, Andrew Wardley. 
Adjuvant trastuzumab for patients with HER2 positive early breast cancer demonstrated 
significant improvements in both disease-free and overall survival with 12 months treatment 
(1, 2), and this was NICE approved in the UK in 2006. When the FinHer trial demonstrated 
similar results with nine weeks trastuzumab (3), there was significant interest in whether 
shorter durations might be as effective. Additional benefits for patients could be less toxicity, 
fewer hospital visits and a more rapid return to normal life, with considerable societal benefits 
of reduced costs. PERSEPHONE was the pragmatic UK duration trial funded by the NIHR HTA, 
which showed that 6 months adjuvant trastuzumab was non-inferior to 12 months with 4-
year disease-free survival rate of 89.4% compared with 89.8% respectively (non-inferiority p 
= 0.01) (4). Less toxicity was reported with 6 months particularly cardiac toxicity and there 
were cost savings over the first 2 years (5), which were maintained over an average patient’s lifetime 
when extrapolated using an economic model. After the publication of these results in June 2019, 
the Optimal Duration of Adjuvant Trastuzumab Working Group was convened, comprising a 
diverse, multi-disciplinary membership. There were representatives from the PERSEPHONE 
Trial Management Group including patient advocates, the NCRI Breast Group, the Association 
of Cancer Physicians (ACP), the Royal College of Radiologists (RCR), and the Independent 
Cancer Patients’ Voice (ICPV). By November 2019, both dual antibody treatment with 
trastuzumab and pertuzumab (https://www.nice.org.uk/guidance/ta569) and extended 
neratinib after single agent trastuzumab (https://www.nice.org.uk/guidance/ta612) had 
been approved by NICE only for those at high risk of recurrence. Therefore, single agent 
trastuzumab remained standard of care for those at lower risk of recurrence and 
recommendations were made for these patients.  
With the aim of assessing current practice and implementation of the PERSEPHONE results, we 
surveyed breast oncologists in the UK, for their views on the recommendations from the 
Working Group for 6 months adjuvant trastuzumab. The following three questions were 
included in the survey: 
1. Do you agree with the following statement? "Patients with HER2-positive breast 
cancer who are receiving adjuvant single agent trastuzumab with chemotherapy 
(concurrent or sequential timing) should be considered for 6 months trastuzumab as 
standard." 
2. Do you agree with the following statement? "Patients receiving adjuvant single agent 
trastuzumab and suffering severe toxicities including cardiac toxicity should be told 
that receiving only 6 months treatment will not result in significant loss of benefit from 
trastuzumab" 
3. Following the results of the PERSEPHONE trial have you reduced trastuzumab duration 
for any of your patients? 
 
The survey was hosted by the University of Warwick and used the QUALTRICS online survey 
tool. It was sent to 330 members of the UK Breast Cancer Group (UKBCG) on 10th January 
2020. The Warwick Clinical Trials Unit sent a reminder one month later to the principal 
investigators and recruiting consultants of the PERSEPHONE sites, the majority of whom were 
in the original mailing.   
One hundred and seventeen out of 330 contacted, returned completed questionnaires (35%) 
from 77 sites. The majority were consultant oncologists (113/117; 97%), more than half of 
whom (65/117; 56%) were practising in Cancer Centres, and 47 (47/117; 40%) in Cancer Units. 
Two thirds of respondents (83/117; 71%) were PERSEPHONE investigators or recruiters.  
Statement 1: 
More than three-quarters of respondents (91/117; 78%, see figure) agreed that for patients 
receiving single agent trastuzumab, 6 months should be considered as standard. Sixty-eight 
did not make any qualifying text comments (68/91; 75%), which represents more than half of 
all respondents (68/117; 58%). 23/91 (25%) of those who agreed with statement 1, qualified 
their response and 11 (48%) considered 6 months trastuzumab standard for patients with a 
lower risk of relapse (usually node negative). Of these 11 respondents, three also limited 6 
months to patients with ER positive tumours, two to patients with T1 and one to T1b tumours. 
Five other comments related to the use of single agent paclitaxel for patients at low risk of 
relapse (APT (6)), and whether the PERSEPHONE results could be applied to these patients. 
One of these five also commented on the use of trastuzumab and pertuzumab in the 
neoadjuvant setting. Two comments mentioned the need for change in national guidelines 
before practice changes. Other comments included: (i) a requirement for longer follow-up; 
(ii) a question about the neratinib treatment pathway; (iii) shared decision-making with 
patients discussing risks and benefits; and (iv) two confirming their support.   
 
Respondents who did not agree with the statement (26/117; 22%) shared comments in half 
(13/26: 50%). Three considered that higher risk patients should be excluded, and 3 felt that 
longer follow-up and an independent meta-analysis were required before any change in 
practice. Three respondents expressed concerns about low risk patients who had already de-
escalated chemotherapy on the APT regimen (6), with one of these highlighting the 
predominant use of anthracyclines in the trial. Two respondents referred to PHARE (7) and 
HORG (8) trials, which had not demonstrated non-inferiority for 6 months. One respondent 
discussed the uncertainties of duration with patients, and one said that with the increase of 
neoadjuvant therapy there was no plan to de-escalate trastuzumab. 
Statement 2: 
Nearly all respondents (114/117; 97%, see figure) agreed with the statement that reassurance 
should be given to patients who had to stop trastuzumab after 6 months because of severe 
toxicities, that there would not be a significant loss of benefit from trastuzumab. Ten 
respondents made a comment (10/114: 9%), with four simply confirming their views. Two 
requested a definition of toxicity, and one suggested a minor rewording of the statement. 
One felt that whilst 12 months should remain the standard, patients who were frail, elderly 
or who had co-morbidities could be reduced to 6 months. One respondent reported that 
advice would depend on patients’ risk profiles and one reported if toxicities were affecting 
QOL then 6 months’ was reasonable. Three respondents who did not agree with the 
statement made no comments. 
Statement 3: 
Just under half the respondents (53/117: 45%, see figure) said they had reduced trastuzumab 
for some of their patients since the PERSEPHONE results were published, and of these 25/53 
(47%) added a comment. The most frequent (19/25: 76%) related to stopping after 6 months 
due to cardiac or other toxicity. Three respondents discussed 6 months treatment with 
patients, two in a selective way with low risk patients and one as routine. This last respondent 
also discussed stopping trastuzumab and pertuzumab after 6 months with a pathological 
complete response to neoadjuvant treatment. One respondent was giving 6 months in T1N0 
patients with paclitaxel only chemotherapy (APT) (6), but expressed concern about reducing 
chemotherapy as well as duration of trastuzumab in these patients. One respondent excluded 
patients receiving neoadjuvant therapy and patients with >3 node positive disease from 6 
months therapy. One had switched to 6 months in all lower risk patients including those 
receiving weekly taxol, and those with concerns about cardiotoxicity. 
Just over half of respondents (64/117: 55%) reported not reducing trastuzumab duration, 
with 24/64 (37.5%) supplying comments. The most common reason was waiting for 
local/national guidelines to change (13/24: 54%, see figure). Three other respondents said 
that for low risk patients they had reduced chemotherapy to paclitaxel only (APT) (6), and for 
high risk patients escalated to dual antibodies. Two respondents said they would only reduce 
trastuzumab duration for toxicity, which one reported they were doing already. Two were not 
involved in decision-making for these patients. Other comments included: ‘not an easy 
change to sell - not complete consensus with colleagues’; ‘not yet’; ‘have offered but none 
have accepted’; ‘considering reduction now there are published results’.  
Single agent taxane regimens 
Nine respondents commented at some point in the questionnaire on low risk patients who 
are receiving paclitaxel for 12 weeks with concurrent trastuzumab continued for 12 months 
(6). The number of patients receiving taxane-only chemotherapy within the PERSEPHONE trial 
is very small (35, 12 month patients and 38, 6 month patients) (9). Hence, it is impossible to 
make any recommendations based on such limited data. However since the trial results as a 
whole confirm non-inferiority for 6 months treatment it is reasonable to conclude that this 
can apply to all types of chemotherapy. 
Summary 
The majority of respondents (78%) agreed that 6-months trastuzumab should be a standard 
option for patients with lower risk disease receiving single agent treatment. In Scotland the 
situation is different and dual therapy is not approved for high risk patients. Hence, we would 
advise that those in Scotland who elsewhere in the UK would be eligible for dual antibody 
therapy or extended neratinib, should continue with 12 months’ trastuzumab. There was a 
clear overwhelming consensus (97%) that with severe toxicity, patients should be reassured 
that stopping at six months would not result in a significant loss of benefit from trastuzumab. 
Although the majority agreed with 6-months for patients with lower risk disease, it was 
notable that over half had not yet introduced this in their clinical practice. This was despite 
an interval of 19 months and 7 months, respectively, since initial presentation (10) and 
subsequent full publication (4) of the PERSEPHONE results. This is not unexpected given the 
well-documented barriers to de-escalation of cancer therapy (11). Although not specifically 
explored in our survey, it is likely that the results of PHARE (7) and the HORG (8) study may 
have led to uncertainty around the strength of the evidence provided by PERSEPHONE. 
However, it is also crucial to recognise that movement towards de-escalation of therapy is 
not determined solely by scientific data. Historical, economic, professional, and social factors 
may all favour entrenched behaviour, even in the face of robust evidence (12). Consistent 
with professional and organisational norms being powerful drivers of clinician behaviour, the 
most common reason given for not reducing trastuzumab duration was waiting for local or 
national guidelines to change. 
The unprecedented crisis of the COVID-19 pandemic significantly increases the acute risks for 
cancer patients attending hospital for treatment. The UKBCG has issued prioritisation 
guidelines for breast cancer treatments (13). On the strength of the PERSEPHONE data, the 
UKBCG executive committee has advised that those at low risk of recurrence receiving single 
agent trastuzumab should stop at 6 months with immediate effect, since the acute risks of 
attending hospital clinics are significant and outweigh any minimal loss of long-term benefit. 
Many hospitals have implemented this prioritisation guidance. 
 
Figure legend: Responses to the three statements within the survey 
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